Evidence map›Paper›PMID 41709026›Full record

ArticleLab animal2026

Methods for randomized, blinded, controlled evaluation of putative disease interventions in multilaboratory, preclinical assessment networks.

Jessica Lamb, Karisma Nagarkatti, Marcio A Diniz, Ryan Cabeen, Monica Estrada, Karen L Crawford, Andre Rogatko, Sungjin Kim, Cenk Ayata, David C Hess and 7 more

Erratum issuedAbstract read
In one paragraph

Article in Lab animal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

17 authors.

Jessica LambDepartment of Physiology and Neuroscience of the Zilkha Neurogenetic Institute of the Keck School of Medicine, Los Angeles, CA, USA. lambj@usc.edu.ORCID 0000-0002-0342-9983
Karisma NagarkattiDepartment of Physiology and Neuroscience of the Zilkha Neurogenetic Institute of the Keck School of Medicine, Los Angeles, CA, USA.
Marcio A DinizBiostatistics and Bioinformatics Research Center, Samuel Oschin Comprehensive Cancer Center, Cedars-Sinai Medical Center, Los Angeles, CA, USA.ORCID 0000-0002-2427-7843
Ryan CabeenUSC Stevens Neuroimaging and Informatics Institute, Los Angeles, CA, USA.
Monica EstradaUSC Stevens Neuroimaging and Informatics Institute, Los Angeles, CA, USA.
Karen L CrawfordUSC Stevens Neuroimaging and Informatics Institute, Los Angeles, CA, USA.
Andre RogatkoBiostatistics and Bioinformatics Research Center, Samuel Oschin Comprehensive Cancer Center, Cedars-Sinai Medical Center, Los Angeles, CA, USA.ORCID 0000-0001-8935-8890
Sungjin KimBiostatistics and Bioinformatics Research Center, Samuel Oschin Comprehensive Cancer Center, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Cenk AyataNeurovascular Research Unit, Department of Neurology, Harvard Medical School, Massachusetts General Hospital, Boston, MA, USA.ORCID 0000-0002-3644-6042
David C HessDepartment of Neurology, Medical College of Georgia, Augusta University, Augusta, GA, USA.
Mohammad Badruzzaman KhanDepartment of Neurology, Medical College of Georgia, Augusta University, Augusta, GA, USA.
Rakesh B PatelDepartment of Internal Medicine, Division of Hematology, Oncology and Blood and Marrow Transplantation, Carver College of Medicine, University of Iowa, Iowa City, IA, USA.ORCID 0000-0001-9727-9738
Mariia KumskovaDepartment of Internal Medicine, Division of Hematology, Oncology and Blood and Marrow Transplantation, Carver College of Medicine, University of Iowa, Iowa City, IA, USA.
Enrique C LeiraDepartment of Neurology, Carver College of Medicine, University of Iowa, Iowa City, IA, USA.
Anil K ChauhanDepartment of Internal Medicine, Division of Hematology, Oncology and Blood and Marrow Transplantation, Carver College of Medicine, University of Iowa, Iowa City, IA, USA.
SPAN Consortium
Patrick LydenDepartment of Physiology and Neuroscience of the Zilkha Neurogenetic Institute of the Keck School of Medicine, Los Angeles, CA, USA.

Funding

UCLA Clinical Translational Science InstituteUL1TR001881 · NCATS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ARLEEN F. BROWN, ARASH NAEIM · 2016 to 2026
$118.1M
Targeting Pyruvate Kinase M2: A novel strategy to combat thrombo-inflammationR35HL139926 · NHLBI · UNIVERSITY OF IOWA · PI CHAUHAN, ANIL KUMAR · 2018 to 2024
$5.3M
The NIH SPAN Coordinating CenterU24NS130600 · NINDS · UNIVERSITY OF SOUTHERN CALIFORNIA · PI LYDEN, PATRICK D · 2023 to 2025
$2.8M
The NIH SPAN Coordinating CenterU24NS113452 · NINDS · UNIVERSITY OF SOUTHERN CALIFORNIA · PI LYDEN, PATRICK D · 2019 to 2021
$2.4M
Novel therpeautic interventions to treat ischemic strokeR01NS109910 · NINDS · UNIVERSITY OF IOWA · PI CHAUHAN, ANIL KUMAR · 2019 to 2023
$1.8M
Mechanisms of Chronic Remote Ischemic Conditioning Induced Cerebroprotection in a VCID ModelR01NS099455 · NINDS · AUGUSTA UNIVERSITY · PI HESS, DAVID C. · 2017 to 2020
$1.5M
Rheoerythrocrine dysfunction in stroke and remote ischemic conditioning (REDS)R01NS112511 · NINDS · AUGUSTA UNIVERSITY · PI HESS, DAVID C. · 2020 to 2023
$1.3M
Multicenter preclinical trial of rho-kinase inhibitor fasudil in acute focal cerebral ischemia and reperfusionU01NS113443 · NINDS · MASSACHUSETTS GENERAL HOSPITAL · PI AYATA, CENK · 2019 to 2021
$1.2M
Stroke Preclinical Assessment Network (SPAN) – Tacilizumab for treatment of acute ischemic strokeU01NS113451 · NINDS · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI ARONOWSKI, JAROSLAW · 2019 to 2021
$1.1M
The University of Iowa Stroke Preclinical Assessment Center for Neuroprotection in strokeU01NS113388 · NINDS · UNIVERSITY OF IOWA · PI CHAUHAN, ANIL KUMAR, LEIRA, ENRIQUE CARLOS · 2019 to 2021
$1.1M
Remote Ischemic Conditioning: A collateral therapeutic and neuroprotectantU01NS113356 · NINDS · AUGUSTA UNIVERSITY · PI HESS, DAVID C. · 2019 to 2021
$1.1M
NCATS NIH HHS UL1 TR001881NHLBI NIH HHS R35 HL139926NINDS NIH HHS R01 NS099455NINDS NIH HHS R01 NS109910NINDS NIH HHS R01 NS112511NINDS NIH HHS U01 NS113356NINDS NIH HHS U01 NS113388NINDS NIH HHS U01 NS113443NINDS NIH HHS U01 NS113451NINDS NIH HHS U24 NS113452NINDS NIH HHS U24 NS130600U.S. Department of Health & Human Services | NIH | National Center for Advancing Translational Sciences (NCATS) UL1 TR001881-01U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke (NINDS) 1U24NS113452-01U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke (NINDS) 1U24NS113452-01 and U24NS113452U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke (NINDS) 5U24NS130600-03U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke (NINDS) NS099455, 1UO1NS113356, and R01NS112511U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke (NINDS) R01 NS099455, 1UO1NS113356, and R01NS112511U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke (NINDS) R35HL139926, R01NS109910, and U01NS113388U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke (NINDS) U01NS113388
6 · The paper itself

Abstract

Science faces a reproducibility crisis, and public trust in science declines when large clinical trials, which had been qualified by promising preclinical studies, fail. While some clinical trial designs may have been inadequate, preclinical assessments of disease interventions might have lacked key elements of rigor such as treatment concealment, randomization, blinded outcomes, prespecified and adequate sample sizes, and models including comorbidities. Here, to demonstrate feasibility and practicality of enhanced rigor in preclinical assessment, we designed a six-laboratory network that implemented rigorous study elements, using acute ischemic stroke for demonstration. This network enrolled 2,615 rodents in 5 different models and implemented a multistage, multiarm statistical design that sequentially eliminated candidate interventions during interim analyses. The methods included centralized intervention packaging, randomization, data quality assessment and data archiving. Blinded analysis of 9,274 video-recorded behavioral tasks and 3,652 magnetic resonance images were evaluated. All tools and protocols are presented and could be adapted to preclinical assessment in other disease areas.

Indexed as

Research DesignStrokeAnimalsDisease Models, AnimalDrug Evaluation, PreclinicalMagnetic Resonance ImagingRandom Allocation

Identifiers

PMID41709026
PMCPMC12956586

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.